Back to news

10x Genomics Expands Global Research in Blood-Based Diagnostics for Autoimmune Disease with Two New Collaborations

PR Newswire•16/11/2026•16:05 ET
0

Key Highlights

  • ➤10x Genomics announces two autoimmune disease research collaborations with Charité, DRFZ and SNU
  • ➤Charité and DRFZ study will follow 750 patients with rheumatoid arthritis, lupus and psoriatic arthritis
  • ➤Collaborations will use Flex Apex to analyze longitudinal blood samples at single-cell resolution
  • ➤SNU study targets biomarkers predicting JAK inhibitor response in moderate-to-severe alopecia areata

Expert Statements

Serge Saxonov, Co-founder and CEO of 10x Genomics

“Clinical decision-making in autoimmune disease depends on symptoms and tests that provide only indirect measures of underlying immune activity, while treatment selection relies on trial and error”

Serge Saxonov, Co-founder and CEO of 10x Genomics

“By studying longitudinal cohorts across diseases, therapies and geographies, these collaborations can help identify robust, reproducible biomarkers of disease activity and treatment response. That evidence could lay the foundation for a new generation of blood-based diagnostics built on single cell measurements of immune activity, moving us closer to precision medicine for patients with autoimmune disease.”

Gerhard Krönke, Director of the Department of Rheumatology and Clinical Immunology at Charité

“Patients with the same rheumatic disease can follow very different courses and respond differently to the same therapy”

Gerhard Krönke, Director of the Department of Rheumatology and Clinical Immunology at Charité

“Following patients over time will allow us to connect shifts in immune biology with clinical outcomes, which is essential to improving care.”

Eicke Latz, Scientific Director of the German Rheumatology Research Center (DRFZ)

“Single cell profiling across a cohort of this size allows us to examine immune activity at a depth not captured by conventional inflammatory markers”

Eicke Latz, Scientific Director of the German Rheumatology Research Center (DRFZ)

“Our goal is to identify robust biomarkers that are consistent across diseases, therapies and patient populations.”

Jong-Il Kim, Head of the Genomic Medicine Institute (GMI) of Seoul National University

“Patients with alopecia areata can respond differently to JAK inhibitor therapy. By linking longitudinal single-cell immune profiles with clinical outcomes, we aim to understand the biology underlying these differences and identify candidate biomarkers of treatment response. We hope this work will provide a foundation for more informed treatment decisions in the future.”

10x Genomics Expands Global Research in Blood-Based Diagnostics for Autoimmune Disease with Two New Collaborations PR Newswire

Collaborations with Charité and DRFZ, and with Seoul National University, aim to identify biomarkers of disease activity and treatment response using 10x's Flex Apex platform

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in